Home › Funds › BROADWOOD CAPITAL INC › LCTX

BROADWOOD CAPITAL INC position in LCTX

LINEAGE CELL THERAPEUTICS IN · Health Care

BROADWOOD CAPITAL INC reported holding 49,560,992 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$64.9M, representing 3.39% of its reported portfolio and ranking #6 among its reported holdings. BROADWOOD CAPITAL INC has disclosed LCTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)49.56M sh
Reported value held$64.92M
Portfolio Weight3.39%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BROADWOOD CAPITAL INC's LCTX position evolved

BROADWOOD CAPITAL INC first disclosed a stake in LCTX in Q3 2023 at 34,935,485 shares (US$41.2M). The position peaked in Q3 2025 at 49,560,992 shares, worth US$83.8M. Across 12 filings, BROADWOOD CAPITAL INC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 49,560,992 shares valued at US$64.9M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 34.94M $41.22M New
Q4 2023 34.94M $38.08M Hold
Q1 2024 41.67M $61.67M Add
Q2 2024 41.67M $41.55M Hold
Q3 2024 41.67M $37.72M Hold
Q4 2024 41.67M $20.94M Hold
Q1 2025 49.56M $22.38M Add
Q2 2025 49.56M $44.97M Hold
Q3 2025 49.56M $83.76M Hold
Q4 2025 49.56M $82.77M Hold
Q1 2026 49.56M $78.31M Hold
Q2 2026 49.56M $64.92M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LCTX and 13F data

LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 36 other funds we track also report a position in LCTX — the largest reported positions include RAFFLES ASSOCIATES LP (US$6.8M), Defender Capital, LLC. (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LCTX

All LCTX fund holders →

FAQ

How long has BROADWOOD CAPITAL INC held LCTX?

BROADWOOD CAPITAL INC has disclosed LCTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BROADWOOD CAPITAL INC's current position in LCTX?

As of Q2 2026, BROADWOOD CAPITAL INC holds 49.56M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $64.92M, representing 3.39% of its reported portfolio and ranking #6.

Has BROADWOOD CAPITAL INC been buying or selling LCTX?

In the latest 13F filing (Q2 2026), BROADWOOD CAPITAL INC held unchanged its position in LCTX. The position peaked in Q3 2025 at 49.56M shares.

Which other funds hold LCTX?

Other major institutional holders of LCTX include RAFFLES ASSOCIATES LP, Defender Capital, LLC., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.